Skip to main content
Livermore
Livermore
ZHEN

Standard Life Aberdeen plc

SEC CIK
0001716774
Latest filing
Jul 31, 2026

The latest 13F from Standard Life Aberdeen plc covers Q2 2026 (filed Jul 31, 2026): 934 long positions worth $71.2B. The top 10 holdings make up 36.8% of the portfolio, and the largest is Apple Inc. (AAPL) at 6.9%. Livermore has 26 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
47
Est. +$472.4M
Added
453
Est. +$2.98B
Reduced
411
Est. −$2.94B
Sold out
44
Est. −$397.1M

Top 5 holdings

Share of this quarter's portfolio value

  1. AAPLApple Inc.
    6.9%$4.88BHistory
  2. NVDANVIDIA Corp
    5.6%$4.00BHistory
  3. MSFTMicrosoft Corp
    4.7%$3.36BHistory
  4. GOOGLAlphabet Inc.
    4.2%$3.00BHistory
  5. AMZNAmazon Com Inc
    4.0%$2.86BHistory

Share of portfolio

Top 5 holdings and the other 929 positions, by share of portfolio value

  1. AAPL6.9%
  2. NVDA5.6%
  3. MSFT4.7%
  4. GOOGL4.2%
  5. AMZN4.0%
  6. Other 929 positions74.6%

Biggest buys

New and added positions, by estimated amount bought

  1. TSLATesla, Inc.
    +$337.8MAddedHistory
  2. AMZNAmazon Com Inc
    +$157.1MAddedHistory
  3. MSFTMicrosoft Corp
    +$101.2MAddedHistory
  4. HONAHoneywell Aerospace Inc.
    +$92.9MNewHistory
  5. UNHUnitedHealth Group Inc
    +$77.9MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. TSLATesla, Inc.
    +0.43 pp2.6% → 3.0%History
  2. GOOGLAlphabet Inc.
    +0.40 pp3.8% → 4.2%History
  3. AMATApplied Materials Inc
    +0.35 pp0.4% → 0.8%History
  4. LRCXLam Research Corp
    +0.28 pp0.4% → 0.6%History
  5. UNHUnitedHealth Group Inc
    +0.23 pp0.4% → 0.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. HONHoneywell International Inc
    −$182.1MSold outHistory
  2. MRVLMarvell Technology, Inc.
    −$120.6MReducedHistory
  3. QUREuniQure N.V.
    −$113.2MReducedHistory
  4. RTXRTX Corp
    −$101.3MReducedHistory
  5. GEVGE Vernova Inc.
    −$92.9MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. HONHoneywell International Inc
    −0.29 pp0.3% → 0.0%History
  2. WMTWalmart Inc.
    −0.20 pp0.8% → 0.6%History
  3. RTXRTX Corp
    −0.17 pp0.2% → <0.1%History
  4. JNJJohnson & Johnson
    −0.16 pp1.0% → 0.9%History
  5. NUNu Holdings Ltd.
    −0.14 pp0.3% → 0.2%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$71.2B
+$9.28B (+15.0%) vs. prior quarter
Positions
934
+3 vs. prior quarter
Top 10 concentration
36.8%
Top 10 as share of value
Turnover
5.0%
Q2 2026, one quarter
Average holding period
20.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $71.2B (Q2 2026)

Q1 2021: $44.0BQ2 2021: $45.7BQ3 2021: $44.4BQ4 2021: $45.5BQ1 2022: $39.1BQ2 2022: $31.8BQ3 2022: $33.6BQ4 2022: $36.8BQ1 2023: $40.0BQ2 2023: $43.0BQ3 2023: $39.2BQ4 2023: $46.1BQ1 2024: $51.0BQ2 2024: $52.2BQ3 2024: $54.5BQ4 2024: $53.3BQ1 2025: $51.3BQ2 2025: $58.8BQ3 2025: $63.2BQ4 2025: $64.6BQ1 2026: $61.9BQ2 2026: $71.2B
Q1 2021Q2 2026
13F filings of Standard Life Aberdeen plc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Jul 31, 2026934$71.2BAAPLNVDAMSFTvs. Q1 2026SEC
Q1 2026Apr 29, 2026931$61.9BAAPLNVDAMSFTvs. Q4 2025SEC
Q4 2025Jan 16, 2026936$64.6BAAPLMSFTNVDAvs. Q3 2025SEC
Q3 2025Nov 7, 2025952$63.2BMSFTAAPLNVDAvs. Q2 2025SEC
Q2 2025Jul 24, 2025951$58.8BMSFTAAPLNVDAvs. Q1 2025SEC
Q1 2025May 13, 2025942$51.3BAAPLMSFTNVDAvs. Q4 2024SEC
Q4 2024Jan 24, 2025931$53.3BMSFTAAPLNVDAvs. Q3 2024SEC
Q3 2024Oct 25, 2024915$54.5BAAPLMSFTNVDAvs. Q2 2024SEC
Q2 2024Aug 9, 2024946$52.2BMSFTAAPLNVDAvs. Q1 2024SEC
Q1 2024May 9, 2024947$51.0BMSFTAAPLNVDAvs. Q4 2023SEC
Q4 2023Jan 31, 2024960$46.1BMSFTAAPLAMZNvs. Q3 2023SEC
Q3 2023Nov 7, 2023888$39.2BMSFTAAPLAMZNvs. Q2 2023SEC
Q2 2023Jun 20, 2024Amended917$43.0BMSFTAAPLAMZNvs. Q1 2023SEC
Q1 2023Jun 20, 2024Amended913$40.0BMSFTAAPLAMZNvs. Q4 2022SEC
Q4 2022Jun 20, 2024Amended915$36.8BMSFTAAPLAMZNvs. Q3 2022SEC
Q3 2022Nov 10, 2022927$33.6BMSFTAAPLAMZNvs. Q2 2022SEC
Q2 2022Aug 5, 2022950$31.8BMSFTAAPLAMZNvs. Q1 2022SEC
Q1 2022May 4, 2022977$39.1BMSFTAAPLAMZNvs. Q4 2021SEC
Q4 2021Feb 10, 2022Amended1,045$45.5BMSFTAAPLAMZNvs. Q3 2021SEC
Q3 2021Nov 15, 20211,043$44.4BMSFTAAPLAMZNvs. Q2 2021SEC
Q2 2021Aug 10, 20211,012$45.7BMSFTAAPLAMZNvs. Q1 2021SEC
Q1 2021May 6, 2021988$44.0BMSFTAAPLAMZN–SEC

13D and 13G filings

Companies where Standard Life Aberdeen plc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

11 companies, largest stake first.

Companies where Standard Life Aberdeen plc owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ELOXEloxx Pharmaceuticals, Inc.13G9.91%400.0K sharesNewJul 27, 20261 filingJul 27, 2026SEC
DTILPrecision Biosciences Inc13G8.88%2.14M sharesNewJan 27, 20261 filingJan 27, 2026SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.13G7.53%1.32M sharesNewJan 16, 20261 filingJan 16, 2026SEC
NSPRInspireMD, Inc.13G/A7.49%3.17M shares+1.54 ppfrom 5.95%Nov 7, 20252 filingsFeb 2, 2026SEC
CDXSCodexis, Inc.13G/A7.45%6.77M shares−1.37 ppfrom 8.82%Jul 30, 20254 filingsJul 20, 2026SEC
SERASera Prognostics, Inc.13G/A7.21%2.75M shares+1.14 ppfrom 6.07%Aug 5, 20252 filingsJul 15, 2026SEC
FRNMFreenome, Inc.13G6.49%578.6K sharesNewApr 28, 20261 filingApr 28, 2026SEC
PRQRProQR Therapeutics N.V.13G6.33%8.93M sharesNewJul 29, 20261 filingJul 29, 2026SEC
TECXTectonic Therapeutic, Inc.13G6.10%1.14M sharesNewJan 29, 20261 filingJan 29, 2026SEC
IMUXImmunic, Inc.13G/A6.05%824.4K shares−0.80 ppfrom 6.85%Jul 31, 20253 filingsJul 16, 2026SEC
EQEquillium, Inc.13G5.30%3.35M sharesNewMay 7, 20261 filingMay 7, 2026SEC

Latest filings

34 filings on file made by Standard Life Aberdeen plc or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Standard Life Aberdeen plc
CompanyFiled (ET)FormStakeChangeEvent dateFiling
PRQRProQR Therapeutics N.V.Jul 29, 20269:48 AM ET13G6.33%8.93M sharesNewJun 30, 2026SEC
ELOXEloxx Pharmaceuticals, Inc.Jul 27, 20267:56 AM ET13G9.91%400.0K sharesNewJun 30, 2026SEC
QUREuniQure N.V.Jul 20, 20269:37 AM ET13G/A4.52%2.85M shares−3.97 ppfrom 8.49%Below 5%Jun 30, 2026SEC
CDXSCodexis, Inc.Jul 20, 20267:08 AM ET13G/A7.45%6.77M shares−1.37 ppfrom 8.82%Jun 30, 2026SEC
IMUXImmunic, Inc.Jul 16, 20266:15 AM ET13G/A6.05%824.4K shares−0.80 ppfrom 6.85%Jun 30, 2026SEC
SERASera Prognostics, Inc.Jul 15, 202610:27 AM ET13G/A7.21%2.75M shares+1.14 ppfrom 6.07%Jun 30, 2026SEC
EQEquillium, Inc.May 7, 202611:09 AM ET13G5.30%3.35M sharesNewApr 1, 2026SEC
QUREuniQure N.V.Apr 30, 20268:21 AM ET13G/A8.49%5.31M shares+2.58 ppfrom 5.91%Apr 1, 2026SEC
QNRXQuoin Pharmaceuticals Ltd.Apr 29, 20266:41 AM ET13G/A4.16%75.0K shares−4.78 ppfrom 8.94%Below 5%Apr 1, 2026SEC
FRNMFreenome, Inc.Apr 28, 20269:38 AM ET13G6.49%578.6K sharesNewApr 1, 2026SEC
NSPRInspireMD, Inc.Feb 2, 202610:35 AM ET13G/A7.49%3.17M shares+1.54 ppfrom 5.95%Dec 31, 2025SEC
IMUXImmunic, Inc.Feb 2, 202610:31 AM ET13G/A6.85%8.24M shares−1.75 ppfrom 8.60%Dec 31, 2025SEC
QUREuniQure N.V.Jan 29, 20263:15 PM ET13G/A5.91%3.68M shares+1.14 ppfrom 4.77%Dec 31, 2025SEC
TECXTectonic Therapeutic, Inc.Jan 29, 20263:15 PM ET13G6.10%1.14M sharesNewDec 31, 2025SEC
QNRXQuoin Pharmaceuticals Ltd.Jan 28, 202611:05 AM ET13G8.94%75.0K sharesNewDec 31, 2025SEC
DTILPrecision Biosciences IncJan 27, 202610:10 AM ET13G8.88%2.14M sharesNewDec 31, 2025SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.Jan 16, 20269:59 AM ET13G7.53%1.32M sharesNewDec 31, 2025SEC
CDXSCodexis, Inc.Jan 15, 20261:42 PM ET13G/A8.82%7.97M shares+4.29 ppfrom 4.53%Dec 31, 2025SEC
CDXSCodexis, Inc.Nov 7, 202511:28 AM ET13G/A4.53%4.09M shares−0.54 ppfrom 5.07%Below 5%Oct 1, 2025SEC
NSPRInspireMD, Inc.Nov 7, 20256:25 AM ET13G5.95%2.48M sharesNewOct 1, 2025SEC